- Osteoporosis in:
- Post-menopausal women
- Male primary or hypogonadal
- Steroid-induced
Dose: SC 20mcg OD. Max 2 yrs use
Injection: 250mcg/mL
- Deliver the dose immediately following removal from refrigerator
- Administer into the thigh or abdominal wall
Recombinant human parathyroid hormone
It stimulates osteoblast function, increases calcium absorption and increases renal tubular reabsorption of calcium leading to increased bone mineral density, bone mass and strength
- Transient hypercalcemia
- Arthralgia
- Asthenia
- Nausea
- Dizziness
- Constipation
- Dyspepsia
- Diarrhea
- Muscle spasms
- Rash
- Insomnia
- Depression
- Vertigo
- Dyspnea
- Vomiting
- Injection site reaction
- Hyperuricemia
- Leg cramps
- Syncope
- Angina
- Hyperhidrosis
- Rhinitis
- Cough
- Pharyngitis
- Pneumonia
- Hypersensitivity to drug/components
- Breastfeeding
- Paget bone disease
- Peds patients
- Open epiphysis
- Bone radiotherapy history
- Skeletal malignancy history
- Bone metastases history
- Metabolic bone disease
- Hereditary osteosarcoma disorder
- Hypercalcemia
- Hyperparathyroidism
WARNING
- Increased risk osteosarcoma in rats dependent on dose and duration, observed at systemic exposure 3-60x human exposure with 20mcg dose
- Prescribe only to patients for whom potential benefits outweigh potential risk
None restricted
Drug Status
| Availability | Prescription only |
| Pregnancy | Category C; weigh risk vs benefit |
| Breastfeeding | Contraindicated |
| Schedule | Not controlled |
| BRAND NAME | STRENGTH | FORMULATION | PACK SIZE | MANUFACTURER | DISTRIBUTOR |
|---|---|---|---|---|---|
| Osteotide | 750mcg/3mL | Injection | 1’s | Virchow Healthcare | Surgipharm Ltd |